Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NVq5bJhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\FXIU6PcLizszN NVvBVXRuPDkEoHi= M1:4VoJtd2OtczCyO{1QUENvaX7keYNm\CClZXzsJJBzd2yrZnXyZZRqd25iY3;tdIFz[WKuZTD0c{B1cGG2IH;mJIJie2GuIHzleoVtew>? M13EbFI3OzVyNU[1
NP69 NUTNV5hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXUTWM2OD1|MT62PeKyOi53NDFOwG0> MnrzNlYzPTJ3N{W=
NP460 M1\SXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHWR3UyUUN3ME2yNk45PcLzMT6xPEDPxE1? M3fmT|I3OjV{NUe1
C666-1 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlG5TWM2OD1zOT65OeKyQC57MzFOwG0> MYSyOlI2OjV5NR?=
C666-1 NXrTZ3p7S2WubDDWbYFjcWyrdImgRZN{[Xl? NEDhVVUyOCEEtV2= Mn7rOFghcA>? NWXCUolpTE2VTx?= MmX0d4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:geIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiY3nzdIxifGmw NIjSR5UzPjJ3MkW3OS=>
C666-1  MlrNSpVv[3Srb36gRZN{[Xl? NEPKRoMyOCEEtV2= MUCyOEBp NHP1VIRFVVOR NV;FS2gy[WO2aY\heIV{KHSqZTDwOVMheGG2aIfhfUwhfXC{ZXf1cIF1cW6pIIC1N{wheDJzIHHu[EBO\G1{ MlizNlYzPTJ3N{W=
C666-1 MX3BdI9xfG:|aYOgRZN{[Xl? MlXsNVAhyrWP NHrmVm01QC95MjDo M2jrOWROW09? MV;z[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzDjbZNxdGG2aX6tbY5lfWOnZDDhdI9xfG:|aYO= M2e2[lI3OjV{NUe1
A549 NILoU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOyOEBp NIr2NVBKSzVyPUG3MlY5KMLzIESuOVIh|ryP M4XFRVI3OTJ3MkOw
A549-NTC NWrZRW0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvPOFMzPCCq NEjyV4ZKSzVyPUG5MlQzKMLzIEGuPVYh|ryP NWnCUY5uOjZzMkWyN|A>
A549-920 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDkU4tMOjRiaB?= M2rvcWlEPTB;M{OuPFUhyrFiND64OEDPxE1? M{TjOVI3OTJ3MkOw
CRL-5908 M1nEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S0R|I1KGh? NYGzOpU2UUN3ME2zPE44OSEEsTCyMlQ{KM7:TR?= MVGyOlEzPTJ|MB?=
L6 NW\TR4l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnSNVDDqM7:TdMg MkT4NlQwPDhxN{KgbC=> MUTEUXNQ MVrpcohq[mm2czDj[YxteyCycn;sbYZmemG2aX;uJIFv\CCmaX\m[ZJmdnSrYYTpc44> NEH6ZWwzPTh5MUe5OC=>
C2C12 NYXhOphxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmqyNVDDqM7:TdMg NEn0TIwzPC92OD:3NkBp MoT6SG1UVw>? NV\wW2ZWcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w NFT2NZQzPTh5MUe5OC=>
MCF-7  NV:y[nJJTnWwY4Tpc44hSXO|YYm= M3[yS|ExyqEQvF2= NFL0VHpFVVOR MXnpcohq[mm2czDjfYNtcW5iREGgZY5lKESrY3XyxsA> NY\UTGp[OjV5MEK3NFM>
DU4475  M1j2WmZ2dmO2aX;uJGF{e2G7 MUW1M|ExNzJyIN88US=> MmH5NlTDqGh? M4DjRoRwf26{ZXf1cIF1\XNiVH;jZU0yKGSxc3Wg[IVx\W6mZX70cJk> NHy1elIzPTV2N{G3OC=>
SMMC-7721 NUTSNXczTnWwY4Tpc44hSXO|YYm= MUOxNEDPxE1? M2fyflQ5KGh? M{i5W2ROW09? M2jqV4NifXOnczDEUmEhTFOEIHThcYFo\Q>? M1HtPFI2PTR2M{[x
SMMC-7721 MX3GeY5kfGmxbjDBd5NigQ>? NGLvVGQyOCEQvF2= NV7rToVKPDhiaB?= MYnEUXNQ MlyzbY5lfWOnczD0bIUh[2i{b33heIlvNWKxdX7kJJBzd3SnaX6gTWZKOTZidH:gdIFzfGmjbHz5JIxw[2GuaYrlJIlvKHSqZTDjfZRweGyjc35CpC=> MkLYNlU2PDR|NkG=
SMMC-7721 M2HmbmZ2dmO2aX;uJGF{e2G7 M{HUfFExKM7:TR?= MX:0PEBp M3fScmROW09? M3;RU4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZtMgTWZPSjIEoH3SUmE> NGXxVI0zPTV2NEO2NS=>
SMMC-7721 NGC4VYpHfW6ldHnvckBCe3OjeR?= NVTrdFN4OTBizszN MX2zOkBp Mn;tSG1UVw>? M2K3VINifXOnczD0bIUh\WO2b4DpZ{BmgHC{ZYPzbY9vKG:oIFnGTVE3 M4PVVlI2PTR2M{[x
MCF-7 MnfSSpVv[3Srb36gRZN{[Xl? NHHuW4QyOMLizszN NET4T5gxNTJ2IHi= NFO3UFlqdmS3Y3XzJJA2OyCjbnSgdFIyN0OrcEG= MoX6NlU1QDJ|N{O=
OVCAR10 NGXIN4NHfW6ldHnvckBCe3OjeR?= MmfKNVDDqM7:TR?= M4LQZVIycMLi M4DTXmROW09? NUXPW5ZrcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? NFS0coczPTR{NkW0PC=>
NCI-H23 NYPrW2d1TnWwY4Tpc44hSXO|YYm= MXqxNOKh|ryP M4DKSFIycMLi Mnm3SG1UVw>? NWOwdXVScW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? MkHMNlU1OjZ3NEi=
A2780 M1HLWWZ2dmO2aX;uJGF{e2G7 MUSxNOKh|ryP NX\Eb5NROjGqwrC= MmnYSG1UVw>? MVXpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz M4r2eVI2PDJ4NUS4
NCI-H23 NFrUUGZHfW6ldHnvckBCe3OjeR?= NV64b4k1OTEEoN88US=> NWfONIdrOjGqwrC= NGnCSYlFVVOR MlLu[IVkemWjc3XzJJRp\SCIb4jNNUBt\X[nbIO= M4\BTFI2PDJ4NUS4
A2780 NH\CZmxHfW6ldHnvckBCe3OjeR?= NEPqT3UyOMLizszN MUSyNYjDqA>? NXjIdY1tTE2VTx?= M3nUeYRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz NVm5PWVOOjV2Mk[1OFg>
HCT116  MmPrSpVv[3Srb36gRZN{[Xl? NWPBNGdzOTBiwsXN NXvNbIoxOjRiaB?= MUnjZZV{\XNiYTDwOVMu\GWyZX7k[Y51KHSndILhdIxwcWRiR{GtZZJz\XO2IHnuJIRqeGyxaXSgTGNVOTF4IHPsc45meyCGMzDhcoQhTDh? MX2yOVM5ODB3NR?=
MCF-10CA1a MUDGeY5kfGmxbjDBd5NigQ>? M33YTlExyqEQvF2= NX\GT2NGPDhiaB?= MnfDSG1UVw>? Mn\0bY5pcWKrdIOgZoF{[WxiaX72ZZNqd25iYX7kJJJm\HWlZXSgWGdHNc7{Mz3pcoR2[2WmIHnueoF{cW:wIITvJIJie2GuIHzleoVtew>? NGLvWXEzPTJ3N{eyPS=>
MCF-10A1  NH7XSZRHfW6ldHnvckBCe3OjeR?= MkfoNVDDqM7:TR?= NYHl[VZyOjRxNEigbC=> M3y0dWROW09? MnHhbY5pcWKrdIOgcYloemG2aX;uJI9nKG6xcn3hcEBjemWjc4Sg[ZBqfGinbHnhcOKh MYmyOVI2Pzd{OR?=
MCF-10CA1a M{jvSmZ2dmO2aX;uJGF{e2G7 MnKwNVDDqM7:TR?= NGKwWmczPCCq MnHRSG1UVw>? NXTmeGpT\GWlcnXhd4V{KHSqZTDUS2Yu|rJ|LXnu[JVk\WRibWLORUBt\X[nbIOgc4ZOVVB{LNMgUW1RQSxiYX7kxsBqdnSnZ4LpcuKh|rMEoEO= M1fmXlI2OjV5N{K5
MCF-10CA1a M1XSSWZ2dmO2aX;uJGF{e2G7 NI\UWFAyOMLizszN MXeyOEBp MYDEUXNQ M{L5[YlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= M{joOlI2OjV5N{K5
SK-BR-7 NFHR[FBHfW6ldHnvckBCe3OjeR?= Mn;rNVDDqM7:TR?= MlH0NlQhcA>? M{H2NWROW09? MXLpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NGf0OYUzPTJ3N{eyPS=>
SUM102PT MkPuSpVv[3Srb36gRZN{[Xl? MX2xNOKh|ryP MViyOEBp M2nRV2ROW09? M{HiXYlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NWrC[WpiOjV{NUe3Nlk>
RAW 264.7 NVLlXWxPTnWwY4Tpc44hSXO|YYm= MVmxNOKh|ryP MoW5N|AhdWmw MV\wdoV3\W62czD0bIUheDV|IILl[JVkfGmxbjDpckBz\XOyb37z[UB1dyCOUGO= MlH3NlUyPzJ3NEe=
RAW 264.7 M3PCTWZ2dmO2aX;uJGF{e2G7 Mor2NVDDqM7:TR?= MorjN|AhdWmw Mn\ZdoVlfWOnczD0bIUhVFCVLXH1[41mdnSnZDD0bIUhVkZvzsrCJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhZ5Rqfmm2eR?= M2fPOlI2OTd{NUS3
RAW 264.7 M1rnT2Z2dmO2aX;uJGF{e2G7 NEf5dFQyOMLizszN Mny1N|AhdWmw NXO1WlFQcW6qaXLpeJMhVFCVLXnu[JVk\WRiTl:gdJJw\HWldHnvcuKh NVvxeY1SOjVzN{K1OFc>
MCF7  M3\RfmNmdGxiVnnhZoltcXS7IFHzd4F6 M4LpfVIvPSEEtV2= MYe1JIQ> NGO4XG5FVVOR NFnmd5R{\W6|aYTpfoV{KE2FRkegeI8hWEGUUDDpcohq[mm2aX;u NHzTbWQzPTB6NUmwNi=>
MCF7  MYHGeY5kfGmxbjDBd5NigQ>? NILnSIIzNjViwsXN MYS0PEBp MWrEUXNQ NXjvR2pn\GWlcnXhd4V{KHSqZTDoc41wdG:pb4XzJGRUSiC{ZYDhbZIh\nKncYXlcoNq\XN? NHzVbHIzPTB6NUmwNi=>
ACHN MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXqwMlUuOTBizszN NXq5epdiOC14IHS= NHnPendFVVOR M{nIZYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIHUdHozPTB4N{e4Oy=>
Caki-2 Ml[yR4VtdCCYaXHibYxqfHliQYPzZZk> MVmwMlUuOTBizszN NUK0ephwOC14IHS= NFLnNphFVVOR MnO0bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmfMNlUxPjd5OEe=
A498 NUW2SWViS2WubDDWbYFjcWyrdImgRZN{[Xl? NFj3UYQxNjVvMUCg{txO MoTsNE03KGR? NFPYO41FVVOR M33DeYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4HwdFI2ODZ5N{i3
115 NYL0UIpoS2WubDDWbYFjcWyrdImgRZN{[Xl? Mly3NE42NTFyIN88US=> NGfYOYYxNTZiZB?= Mlq4SG1UVw>? NVjSWI1KcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NX\acXBJOjVyNke3PFc>
117 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkLCNE42NTFyIN88US=> M3;ZOVAuPiCm MoT0SG1UVw>? NYLMNYdXcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWjKUYhnOjVyNke3PFc>
ACHN M3;Sb2Z2dmO2aX;uJGF{e2G7 MYGwMlUwOS93IN88US=> NE\JSFk1QCCq MnP3SG1UVw>? MnLEcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? MVKyOVA3Pzd6Nx?=
Caki-2 NHLRcHBHfW6ldHnvckBCe3OjeR?= NHzkUpQxNjVxMT:1JO69VQ>? Mme2OFghcA>? NECwb2xFVVOR M3K1coxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NUTpbpZbOjVyNke3PFc>
A498 M2\kbGZ2dmO2aX;uJGF{e2G7 MkPBNE42NzFxNTFOwG0> MnzROFghcA>? M4CzcmROW09? MV;s[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? NYr1eINVOjVyNke3PFc>
115 MlLHSpVv[3Srb36gRZN{[Xl? NEDlU2sxNjVxMT:1JO69VQ>? MUK0PEBp NXeyTJB4TE2VTx?= Mn7GcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NEPjRVYzPTB4N{e4Oy=>
ACHN MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvEc|VPPSEQvF2= MXK0PEBp M3TaPGROW09? MY\pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= M330dVI2ODZ5N{i3
Caki-2 MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfUOUDPxE1? NH63TmM1QCCq MUnEUXNQ MkLzbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg M3\BR|I2ODZ5N{i3
A498 NFKzSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX21JO69VQ>? NY\IeZVCPDhiaB?= MX7EUXNQ M2P5U4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NGrNXoUzPTB4N{e4Oy=>
115 NGe2e4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnnOUDPxE1? NXrpfmd4PDhiaB?= MknGSG1UVw>? M4nMTIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NXPvdHRwOjVyNke3PFc>
ACHN M4rDdmZ2dmO2aX;uJGF{e2G7 NWLSOZBMPSEQvF2= MVW0PEBp NV7EfWU{TE2VTx?= NEXqT2NqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg MoPCNlUxPjd5OEe=
Caki-2 NVrFNmJwTnWwY4Tpc44hSXO|YYm= NEjCUXU2KM7:TR?= Ml3xOFghcA>? NIXCcodFVVOR MVTpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi MX2yOVA3Pzd6Nx?=
A498 MYXGeY5kfGmxbjDBd5NigQ>? MXK1JO69VQ>? M13ydVQ5KGh? MUjEUXNQ M13Vfolv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NFv3b3UzPTB4N{e4Oy=>
115 NYXEXFI4TnWwY4Tpc44hSXO|YYm= NHHMNHE2KM7:TR?= M1[zNFQ5KGh? M2HLWGROW09? M4HRd4lv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= MmHHNlUxPjd5OEe=
MOLM-13 M4DVOWZ2dmO2aX;uJGF{e2G7 NULlW5hGPsLizszN MXiwMVghcA>? MWXEUXNQ NIfsUotqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDwOVMtKE2GTUKsJJAzOSCjbnSgZYNmfHmuYYTl[EBxPTN? NY[0TnZbOjR6OEWwPFI>
MOLM-13 NYnSVGdETnWwY4Tpc44hSXO|YYm= NHfsNZY3yqEQvF2= NXPlV|V[PiCq M{fzR2ROW09? NUjBd3hD\W6qYX7j[ZMhfGinIHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhUDKEIHHu[EBp\WG2IIPoc4NsKHC{b4TlbY5{KEi|cEK3JIFv\CCKc4C5NC=> NXXzVXA{OjR6OEWwPFI>
HepG2 M4\wO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;nZVYyPzJiaB?= NH\4NW9FVVOR NXvucI97UUN3ME2zOU45PiEEsTCyMlkh|ryP MYmyOFg5PDhyOR?=
HepG2/As NWG0T2FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP0eWNCPzJiaB?= NHrZcFBFVVOR MorBTWM2OD14OD6xN{DDuSB7Lk[g{txO NYXHT2YxOjR6OES4NFk>
SMMC7721 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXhdpg4OiCq MlXDSG1UVw>? MXXJR|UxRTNzLkK4JOKyKDRwMjFOwG0> MmXLNlQ5QDR6MEm=
SMMC7721/Ac Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjrbHg4OiCq NE\wWHVFVVOR MWjJR|UxRTV3LkKxJOKyKDVwMEOg{txO Ml\vNlQ5QDR6MEm=
Huh-7 MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVK3NkBp M1:zdGROW09? M2LNcmlEPTB;M{OuPVYhyrFiMz65JO69VQ>? MmDvNlQ5QDR6MEm=
Hep3B NVzqXWJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK3eHI6PzJiaB?= NH\OU|BFVVOR NFXQRnVKSzVyPUKwMlE5KMLzIEGuPFQh|ryP NWP1Wm9vOjR6OES4NFk>
HepG2 NXS2VZhySXCxcITvd4l{KEG|c3H5 NHLVfmdqdmS3Y3XzJIFxd3C2b4Ppdy=> MWOyOFg5PDhyOR?=
SMMC7721 NXiwUpBJSXCxcITvd4l{KEG|c3H5 M2XiZ4lv\HWlZYOgZZBweHSxc3nz NFS2Z4wzPDh6NEiwPS=>
Huh-7 MWDBdI9xfG:|aYOgRZN{[Xl? NFTKNVlqdmS3Y3XzJIFxd3C2b4Ppdy=> NFe1XpYzPDh6NEiwPS=>
Hep3B NIjpNoRCeG:ydH;zbZMhSXO|YYm= MVfpcoR2[2W|IHHwc5B1d3Orcx?= NV;QPXZmOjR6OES4NFk>
U2OS  NHOzUXFHfW6ldHnvckBCe3OjeR?= MXqyNEDPxE1? NF7vT40zPCCq Mn;mbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKhSkOOMlGxMEBDS0y[TNMgZY5lSkOOVx?= NXG5UWZnOjR6NkeyOVk>
AML2 NF;ZV4hCeG:ydH;zbZMhSXO|YYm= MYmyM|ExKM7:TR?= MnewNlQwPDhiaB?= M4KyfIlv\HWlZYOgZZBweHSxc3nz MWmyOFY2QTd2OR?=
MOML13 M3Tn[GFxd3C2b4Ppd{BCe3OjeR?= NVLBNZpKOi9zMDFOwG0> NXXIOlNNOjRxNEigbC=> NF7sXFJqdmS3Y3XzJIFxd3C2b4Ppdy=> NGfxb5ozPDZ3OUe0PS=>
AML2 MluwSpVv[3Srb36gRZN{[Xl? MUexNO69VQ>? NXK5Woc4Oi92IHi= NFntOoJqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> M3SyXFI1PjV7N{S5
AML3 NEPBRlBHfW6ldHnvckBCe3OjeR?= MUCxNO69VQ>? M{HjZVIwPCCq MlL5bY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= NGXRWIszPDZ3OUe0PS=>
MOML13 NFLkdmJHfW6ldHnvckBCe3OjeR?= MkjnNVDPxE1? MmG3Nk81KGh? MYDpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= NVPMeGYxOjR4NUm3OFk>
BeWo MV3GeY5kfGmxbjDBd5NigQ>? MljVN|AhyrWP Mnm4NlQhcA>? NWCzbGt3cW6lcnXhd4V{KHB3MzygUYRuOixicEKxJIFv\CCSdX3hJIF1KHSqZTDwdo91\WmwIHzleoVt MVyyOFQ6QDF3NB?=
BeWo NH\iOG5CeG:ydH;zbZMhSXO|YYm= M3jSXlMxKML3TR?= MUmyOEBp NFe2OlZqdmO{ZXHz[ZMh[XCxcITvd4l{ Mmj6NlQ1QThzNUS=
OCI M3u0PWZ2dmO2aX;uJGF{e2G7 NEjZeGgyOCEQvF2= NEGzNXEzPCCq NVm5Z4tnfXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u MYeyOFQ4OzV4Mh?=
MOLM NUTDfo1rTnWwY4Tpc44hSXO|YYm= MoHLNVAh|ryP M{PCcFI1KGh? MYL1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? NVj0T4F6OjR2N{O1OlI>
U2OS  MlLoSpVv[3Srb36gRZN{[Xl? NXLJTpBVOjBizszN NHfpd|kzPCCq MWTpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv MWeyOFM3PjByNx?=
RKO MV\GeY5kfGmxbjDBd5NigQ>? NWXvWZJ6OjBizszN NV6yfIhIOjRiaB?= NHHDSHhqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw MkDZNlQ{PjZyMEe=
U2OS  MYXGeY5kfGmxbjDBd5NigQ>? M3XrfFIxKM7:TR?= NGDUV3ozPCCq M1;OU4lv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u MVmyOFM3PjByNx?=
RKO MmfUSpVv[3Srb36gRZN{[Xl? NHrnUYozOCEQvF2= M3PRXlI1KGh? NXLrcpdFcW6mdXPld{BJVy1zIHX4dJJme3Orb36gZZQhfGinIHzleoVtKG:oIITyZY5{[3KrcITpc44> NFvyXW8zPDN4NkCwOy=>
SMMC-7721  MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWW0S4JUOS5{NT2yNEDPxE1? MoTUNlQwPDhxN{KgbC=> NILFW5lFVVOR M3vz[IlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 M1X4OFI1Ojh4M{Gy
HuH-7 MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2rLUlEvOjVvMkCg{txO NXXE[pc1OjRxNEivO|IhcA>? M3HtZmROW09? NILjbW1qdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NVfIZlYxOjR{OE[zNVI>
SMMC-7721  NXiz[2lpSXCxcITvd4l{KEG|c3H5 NGHrcGIzOCEQvF2= NX\6PGJ6PDhiaB?= MX;EUXNQ Mn6xbY5lfWOnczDhdI9xfG:|aYO= MWWyOFI5PjNzMh?=
HuH-7 M{nNUmFxd3C2b4Ppd{BCe3OjeR?= M1X5XlIxKM7:TR?= NF\ZXlA1QCCq MljlSG1UVw>? NGLlR21qdmS3Y3XzJIFxd3C2b4Ppdy=> M1;kfVI1Ojh4M{Gy
SMMC-7721  M4\qO2Z2dmO2aX;uJGF{e2G7 Mmm3NVAh|ryP NUGwZYd4OzZiaB?= M{[1dGROW09? NHLoPVhld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>? MVKyOFI5PjNzMh?=
HuH-7 MkSySpVv[3Srb36gRZN{[Xl? NYTLeodzOTBizszN MojaN|YhcA>? NXHYNoM4TE2VTx?= NUKwSHNs\G:5bj3y[Yd2dGG2ZYOgeIhmKHC{b4TlbY4h\XiycnXzd4lwdiCuZY\lcEBw\iCyaH;zdIhwNVOnckO5Nk1xPTN? NIHlWWozPDJ6NkOxNi=>
AT2 NGH0R4NHfW6ldHnvckBCe3OjeR?= NGj2[pQ2NzFyIN88US=> M{LUNIxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li MnXhNlQzPDB{MEO=
REH M4TNWGZ2dmO2aX;uJGF{e2G7 MnvDOU8yOCEQvF2= NXrWU5U6dGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= MXSyOFI1ODJyMx?=
UoCB6 NXT6bHVNTnWwY4Tpc44hSXO|YYm= NHzic5k2NzFyIN88US=> M4\hWoxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li M3\4clI1OjRyMkCz
AT2 NIrONY5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{\DNFAuOjVizszN MlfxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NX;tVHhWOjR{NECyNFM>
REH MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF\QRmgxNTJ3IN88US=> MXXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MVmyOFI1ODJyMx?=
UoCB6 MnW0R4VtdCCYaXHibYxqfHliQYPzZZk> M{HD[VAuOjVizszN M{DseIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M4HxSlI1OjRyMkCz
A2780 MW\GeY5kfGmxbjDBd5NigQ>? MlS0OU8yOC9{MDFOwG0> M1rqbVI1KGh? M1PQ[JVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi MkTkNlQyOzZzNEe=
H460 M{X0SGZ2dmO2aX;uJGF{e2G7 M3XRblUwOTBxMkCg{txO NF32cIszPCCq MmHGeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? NF7w[YkzPDF|NkG0Oy=>
Lovo  NWWzTXVyTnWwY4Tpc44hSXO|YYm= NX[xUXZIPS9zMD:yNEDPxE1? NFLNTnYzPCCq MlrleZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? NH;IVnQzPDF|NkG0Oy=>
A2780 NG\6fWtCeG:ydH;zbZMhSXO|YYm= NGS3XpU2NzFyL{KwJO69VQ>? MY[yOEBp NUjFSGdv\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? M33YZ|I1OTN4MUS3
H460 MVrBdI9xfG:|aYOgRZN{[Xl? NXXWeGU2PS9zMD:yNEDPxE1? NF\v[2gzPCCq MV7lcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> NF7MUIEzPDF|NkG0Oy=>
Lovo  MW\BdI9xfG:|aYOgRZN{[Xl? M{DHRlUwOTBxMkCg{txO M2DHd|I1KGh? NX7wSnFo\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? M2rzZ|I1OTN4MUS3

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID